Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Launch Notification Delay Remains In The US, Might Not Matter For Newer Products

This article was originally published in SRA

Executive Summary

The US Court of Appeals for the Federal Circuit has ruled that a biosimilar applicant is required to provide 180-day notice of its commercial marketing after Food and Drug Administration approval whether or not it engages in the patent information exchange process laid out in the biosimilar statute1. But the court suggested that notification could be given at the time of tentative approval, which would prevent a marketing delay for biosimilar versions of newer biologics.

Advertisement

Related Content

Biosimilar Litigation: Genentech Avastin Suit Tossed; Janssen Remicade Case Uncertain
Biosimilar Launch Notification: Solicitor General Backs Pre-FDA Approval Notice
Biosimilar Launch Notification May Head Back To Court
Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues

Topics

Advertisement
UsernamePublicRestriction

Register

PS118717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel